The Gates Foundation, Novo Nordisk Foundation and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment that will focus on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback